Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Elaine Lam

Concepts (314)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
37
2026
231
6.950
Why?
Kidney Neoplasms
40
2026
419
6.480
Why?
Prostatic Neoplasms
13
2023
972
2.800
Why?
Neoplasms, Germ Cell and Embryonal
3
2023
76
1.410
Why?
Antineoplastic Agents
15
2024
2219
1.270
Why?
Prostate-Specific Antigen
4
2023
162
1.130
Why?
Antibodies, Monoclonal, Humanized
12
2025
992
1.100
Why?
Protein Kinase Inhibitors
12
2026
983
1.010
Why?
Antineoplastic Combined Chemotherapy Protocols
15
2025
1998
0.980
Why?
Testicular Neoplasms
3
2023
108
0.900
Why?
Neoplasms, Unknown Primary
1
2025
20
0.880
Why?
Neoplasms
10
2023
2954
0.870
Why?
Antineoplastic Agents, Immunological
2
2025
200
0.820
Why?
Carcinoma, Transitional Cell
4
2025
70
0.780
Why?
Seminoma
2
2021
20
0.770
Why?
Carcinoma, Medullary
2
2013
16
0.700
Why?
Aged
37
2026
26432
0.670
Why?
Retroperitoneal Neoplasms
1
2021
28
0.660
Why?
Urinary Bladder Neoplasms
4
2025
259
0.650
Why?
Male
60
2026
73396
0.640
Why?
Pyridines
6
2026
610
0.630
Why?
Pneumocystis carinii
1
2020
12
0.620
Why?
Teratoma
1
2021
121
0.620
Why?
Carcinoma, Squamous Cell
1
2025
628
0.620
Why?
Spinal Cord Compression
1
2020
24
0.610
Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
43
0.610
Why?
Pneumonia, Pneumocystis
1
2020
34
0.610
Why?
Euterpe
1
2018
4
0.570
Why?
Humans
87
2026
146342
0.560
Why?
TWEAK Receptor
1
2017
6
0.530
Why?
Middle Aged
39
2026
36619
0.530
Why?
Prednisone
3
2020
229
0.520
Why?
Pyrazoles
3
2022
517
0.510
Why?
Anilides
5
2023
83
0.510
Why?
Abiraterone Acetate
1
2017
15
0.500
Why?
Sulfonamides
3
2015
594
0.500
Why?
Biomarkers, Tumor
6
2025
1339
0.490
Why?
Adrenal Cortex Hormones
1
2020
486
0.490
Why?
Plant Extracts
1
2018
192
0.490
Why?
Aged, 80 and over
17
2025
8391
0.470
Why?
Neoplasm Metastasis
9
2020
693
0.450
Why?
Antineoplastic Agents, Hormonal
2
2015
196
0.450
Why?
Neoplasm Recurrence, Local
3
2023
1160
0.440
Why?
Carcinoma, Papillary
1
2015
83
0.430
Why?
Brain Neoplasms
2
2021
1325
0.430
Why?
Paclitaxel
3
2022
260
0.410
Why?
Everolimus
2
2025
112
0.410
Why?
Patient Reported Outcome Measures
4
2025
516
0.410
Why?
Interleukin-2
2
2014
434
0.400
Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
54
0.400
Why?
Neoplasms, Complex and Mixed
1
2013
7
0.400
Why?
Antibodies, Monoclonal
2
2017
1512
0.380
Why?
Urologic Neoplasms
2
2025
31
0.370
Why?
Treatment Outcome
17
2025
11821
0.350
Why?
Nephrectomy
4
2024
172
0.350
Why?
Retrospective Studies
18
2024
17438
0.350
Why?
Epothilones
1
2011
2
0.350
Why?
Angiomyolipoma
1
2011
21
0.340
Why?
Androgen Antagonists
3
2020
91
0.340
Why?
Carcinoma, Non-Small-Cell Lung
3
2025
1195
0.340
Why?
Deoxycytidine
2
2010
219
0.330
Why?
Multicenter Studies as Topic
1
2012
417
0.320
Why?
Benzenesulfonates
1
2010
23
0.310
Why?
Suramin
1
2010
8
0.310
Why?
Lung Neoplasms
4
2025
2675
0.310
Why?
Adult
27
2025
41087
0.310
Why?
Maximum Tolerated Dose
6
2022
217
0.290
Why?
Radiosurgery
3
2019
398
0.280
Why?
Female
35
2026
79499
0.280
Why?
Immunotherapy
5
2024
671
0.270
Why?
Indenes
2
2025
6
0.270
Why?
Fluorouracil
1
2008
231
0.260
Why?
Disease Progression
3
2021
2867
0.260
Why?
Bone Neoplasms
2
2023
272
0.250
Why?
Quinazolines
1
2008
267
0.250
Why?
Chemotherapy, Adjuvant
3
2013
429
0.240
Why?
Neoplasm Staging
7
2017
1488
0.240
Why?
Practice Guidelines as Topic
4
2024
1591
0.240
Why?
Platinum
2
2024
48
0.240
Why?
Drug Administration Schedule
3
2021
790
0.230
Why?
Proto-Oncogene Proteins c-kit
1
2026
73
0.230
Why?
Thyroid Neoplasms
1
2010
380
0.230
Why?
Sulfones
2
2017
127
0.220
Why?
B7-H1 Antigen
2
2025
245
0.220
Why?
Microsatellite Instability
1
2025
57
0.220
Why?
Prognosis
5
2023
4351
0.220
Why?
Phenylurea Compounds
4
2016
122
0.220
Why?
Benzoxazoles
2
2022
20
0.200
Why?
Melanoma
2
2025
765
0.200
Why?
Ipilimumab
2
2021
44
0.200
Why?
Taste
1
2026
237
0.200
Why?
Taxoids
2
2017
115
0.200
Why?
Taste Buds
1
2026
214
0.190
Why?
Multiple Sclerosis
2
2019
435
0.190
Why?
Bevacizumab
2
2020
169
0.180
Why?
Kaplan-Meier Estimate
5
2024
970
0.180
Why?
Pyrimidines
3
2022
532
0.170
Why?
Quantitative Trait Loci
1
2024
388
0.170
Why?
Mastectomy
1
2023
189
0.170
Why?
Remission, Spontaneous
1
2021
39
0.170
Why?
Administration, Oral
4
2024
872
0.160
Why?
Biliary Tract Neoplasms
1
2021
30
0.160
Why?
Celecoxib
2
2012
41
0.160
Why?
Neoplasm, Residual
1
2021
143
0.160
Why?
Carboplatin
1
2021
168
0.160
Why?
Phosphatidylinositol 3-Kinases
1
2022
384
0.160
Why?
Bariatric Surgery
1
2024
250
0.160
Why?
Syndrome
1
2021
380
0.160
Why?
Proto-Oncogene Proteins c-akt
1
2022
441
0.160
Why?
Combined Modality Therapy
4
2019
1271
0.160
Why?
Quality of Life
2
2025
3200
0.150
Why?
Genomics
1
2025
853
0.150
Why?
Azepines
1
2020
104
0.150
Why?
Cancer Care Facilities
1
2020
48
0.150
Why?
Antiemetics
1
2020
51
0.150
Why?
Thrombosis
1
2023
398
0.150
Why?
Homologous Recombination
1
2019
38
0.150
Why?
Fatal Outcome
1
2020
302
0.150
Why?
TOR Serine-Threonine Kinases
1
2022
455
0.150
Why?
Morpholines
1
2020
130
0.140
Why?
MAP Kinase Kinase Kinases
1
2019
70
0.140
Why?
Streptococcus
1
2019
26
0.140
Why?
Pharyngitis
1
2019
28
0.140
Why?
Disease-Free Survival
4
2016
778
0.140
Why?
Fruit and Vegetable Juices
1
2018
23
0.140
Why?
Drug Hypersensitivity
1
2020
93
0.140
Why?
Anti-Bacterial Agents
2
2020
1942
0.140
Why?
Diagnosis, Computer-Assisted
1
2019
92
0.140
Why?
Feedback
1
2019
183
0.140
Why?
Mutation
2
2025
4093
0.140
Why?
Indans
1
2017
12
0.130
Why?
Neoplastic Cells, Circulating
2
2016
81
0.130
Why?
Cost-Benefit Analysis
1
2021
640
0.130
Why?
Interferon beta-1b
1
2017
2
0.130
Why?
Pancreatic Neoplasms
1
2026
944
0.130
Why?
Proton Therapy
1
2017
16
0.130
Why?
Niacinamide
3
2016
103
0.120
Why?
Liver Neoplasms
1
2023
776
0.120
Why?
Erythrocytes, Abnormal
1
2016
14
0.120
Why?
Genome-Wide Association Study
1
2024
1537
0.120
Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
66
0.120
Why?
Dose-Response Relationship, Drug
3
2022
2022
0.120
Why?
Hematologic Diseases
1
2016
66
0.120
Why?
Polymorphism, Single Nucleotide
1
2024
2240
0.120
Why?
DNA Damage
1
2019
439
0.120
Why?
Streptococcal Infections
1
2019
179
0.120
Why?
Cell Line, Tumor
3
2020
3545
0.120
Why?
Oncolytic Virotherapy
1
2015
13
0.120
Why?
Neoadjuvant Therapy
2
2023
475
0.120
Why?
Problem Solving
1
2017
155
0.120
Why?
Indazoles
2
2015
86
0.110
Why?
Mammalian orthoreovirus 3
1
2015
38
0.110
Why?
Autoimmune Diseases
1
2020
467
0.110
Why?
Angiopoietin-1
1
2015
12
0.110
Why?
Angiopoietin-2
1
2015
15
0.110
Why?
Pyrroles
1
2016
222
0.110
Why?
Fatigue
2
2022
363
0.110
Why?
Genetic Predisposition to Disease
1
2024
2488
0.110
Why?
Receptor, IGF Type 1
1
2015
64
0.110
Why?
Imidazoles
2
2015
245
0.110
Why?
Kidney Glomerulus
1
2015
129
0.110
Why?
Radiation Tolerance
1
2015
101
0.110
Why?
Proto-Oncogene Proteins p21(ras)
1
2015
250
0.110
Why?
Nanoparticles
1
2021
523
0.100
Why?
Soft Tissue Neoplasms
1
2015
133
0.100
Why?
Severity of Illness Index
2
2019
2921
0.100
Why?
Magnetic Resonance Imaging
2
2021
3926
0.100
Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
109
0.100
Why?
Prefrontal Cortex
1
2017
339
0.100
Why?
Prostatectomy
1
2013
93
0.100
Why?
Patient Satisfaction
1
2017
706
0.090
Why?
Glycine
1
2014
184
0.090
Why?
Indoles
1
2016
511
0.090
Why?
Cohort Studies
5
2021
6077
0.090
Why?
Recombinant Fusion Proteins
1
2015
663
0.090
Why?
Glomerular Filtration Rate
1
2015
745
0.090
Why?
Quinolines
1
2013
191
0.090
Why?
Tubulin Modulators
1
2011
10
0.090
Why?
Emotions
1
2017
559
0.090
Why?
Metabolic Clearance Rate
1
2011
115
0.080
Why?
Algorithms
1
2019
1849
0.080
Why?
Arthralgia
1
2011
66
0.080
Why?
Area Under Curve
1
2011
335
0.080
Why?
Clinical Trials as Topic
1
2015
1064
0.080
Why?
Diarrhea
1
2011
190
0.080
Why?
Peripheral Nervous System Diseases
1
2011
135
0.080
Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
141
0.080
Why?
Breast Neoplasms
1
2023
2418
0.080
Why?
Molecular Structure
1
2011
484
0.080
Why?
Proto-Oncogene Proteins c-ret
1
2010
41
0.080
Why?
Biopsy
1
2013
1075
0.080
Why?
Survival Rate
3
2020
2092
0.080
Why?
Nomograms
1
2010
59
0.070
Why?
Decision Making
1
2017
993
0.070
Why?
Immunohistochemistry
1
2013
1712
0.070
Why?
Tomography, X-Ray Computed
3
2022
2786
0.070
Why?
Radiotherapy, Adjuvant
1
2010
222
0.070
Why?
Drug Synergism
1
2010
354
0.070
Why?
Capecitabine
1
2008
56
0.070
Why?
Infusions, Intravenous
1
2010
432
0.070
Why?
Adenine
2
2022
339
0.070
Why?
Positron-Emission Tomography
1
2010
343
0.070
Why?
Proteinuria
1
2008
103
0.070
Why?
Hypertension, Pregnancy-Induced
1
2008
69
0.060
Why?
Dysgeusia
1
2026
5
0.060
Why?
Young Adult
4
2024
14330
0.060
Why?
Follow-Up Studies
3
2020
5439
0.060
Why?
Creatinine
1
2008
511
0.060
Why?
Risk
1
2008
920
0.060
Why?
Optical Illusions
1
2005
2
0.050
Why?
Urothelium
1
2025
33
0.050
Why?
Von Hippel-Lindau Tumor Suppressor Protein
1
2024
19
0.050
Why?
Risk Factors
2
2020
10921
0.050
Why?
Cell Lineage
1
2026
377
0.050
Why?
Cytoreduction Surgical Procedures
1
2024
69
0.050
Why?
Prospective Studies
3
2021
8123
0.050
Why?
Mastectomy, Segmental
1
2023
107
0.050
Why?
Adjuvants, Immunologic
1
2024
245
0.050
Why?
RNA Interference
1
2024
472
0.050
Why?
Cardiovascular Diseases
1
2014
2219
0.040
Why?
Disease Management
2
2017
651
0.040
Why?
RNA, Small Interfering
1
2024
633
0.040
Why?
Cisplatin
1
2023
347
0.040
Why?
Nephritis, Interstitial
1
2020
11
0.040
Why?
International Agencies
1
2020
30
0.040
Why?
Aurora Kinase A
1
2020
57
0.040
Why?
Drug Evaluation
1
2020
78
0.040
Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.040
Why?
Lymphocytes
1
2022
379
0.040
Why?
Nausea
1
2020
111
0.040
Why?
Analysis of Variance
2
2017
1298
0.040
Why?
Hong Kong
1
2019
7
0.040
Why?
Vomiting
1
2020
131
0.040
Why?
Lymphatic Metastasis
1
2020
335
0.040
Why?
Time Factors
1
2010
7109
0.040
Why?
Sex Factors
1
2025
2107
0.040
Why?
Mice, Knockout
1
2026
3125
0.040
Why?
Hospitals
1
2023
738
0.040
Why?
Medical Oncology
1
2022
345
0.030
Why?
DNA-Binding Proteins
1
2026
1468
0.030
Why?
Cell Differentiation
1
2026
1982
0.030
Why?
Central Nervous System
1
2020
278
0.030
Why?
Transcription Factors
1
2026
1730
0.030
Why?
Retreatment
1
2017
79
0.030
Why?
Genetic Testing
1
2020
492
0.030
Why?
Databases, Factual
1
2023
1493
0.030
Why?
Drug Therapy, Combination
1
2020
1036
0.030
Why?
Receptor Protein-Tyrosine Kinases
1
2019
227
0.030
Why?
United States
2
2017
16136
0.030
Why?
National Cancer Institute (U.S.)
1
2017
56
0.030
Why?
Xenograft Model Antitumor Assays
1
2020
930
0.030
Why?
Erythrocyte Indices
1
2016
33
0.030
Why?
Anti-Inflammatory Agents
1
2020
474
0.030
Why?
Academic Medical Centers
1
2020
561
0.030
Why?
Antimicrobial Stewardship
1
2019
136
0.030
Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
266
0.030
Why?
Case-Control Studies
1
2024
3647
0.030
Why?
Neutrophils
1
2022
1133
0.030
Why?
Clinical Decision-Making
1
2019
365
0.030
Why?
Mice
2
2026
18297
0.030
Why?
Acute Disease
1
2019
1038
0.030
Why?
Thoracic Neoplasms
1
2015
40
0.030
Why?
Abdominal Neoplasms
1
2015
48
0.030
Why?
Tosyl Compounds
1
2015
17
0.030
Why?
Antibodies, Neoplasm
1
2015
34
0.030
Why?
Kidney Function Tests
1
2015
156
0.030
Why?
Reaction Time
1
2017
438
0.030
Why?
Angiogenesis Inhibitors
1
2016
239
0.030
Why?
Craniocerebral Trauma
1
2017
173
0.030
Why?
Neoplasm Grading
1
2015
313
0.030
Why?
Radiotherapy
1
2015
209
0.030
Why?
Organ Size
1
2015
465
0.030
Why?
Postoperative Period
1
2015
355
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2015
150
0.030
Why?
Drug Resistance, Neoplasm
1
2020
893
0.030
Why?
Demography
1
2015
274
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2015
143
0.030
Why?
STAT5 Transcription Factor
1
2014
51
0.030
Why?
Animals
3
2026
38107
0.030
Why?
Nitriles
1
2015
212
0.020
Why?
Recurrence
1
2017
1133
0.020
Why?
Drug Interactions
1
2015
405
0.020
Why?
Gonadotropin-Releasing Hormone
1
2015
215
0.020
Why?
Medication Adherence
1
2017
535
0.020
Why?
ErbB Receptors
1
2015
636
0.020
Why?
Cell Survival
1
2015
1105
0.020
Why?
Longitudinal Studies
1
2020
3017
0.020
Why?
Proportional Hazards Models
1
2015
1331
0.020
Why?
Neuropsychological Tests
1
2017
1149
0.020
Why?
Double-Blind Method
1
2016
2070
0.020
Why?
Molecular Targeted Therapy
1
2014
447
0.020
Why?
T-Lymphocytes, Regulatory
1
2014
415
0.020
Why?
Proto-Oncogene Proteins
1
2014
616
0.020
Why?
Biomarkers
1
2022
4340
0.020
Why?
Enzyme Inhibitors
1
2014
823
0.020
Why?
Cell Cycle Proteins
1
2014
630
0.020
Why?
Logistic Models
1
2015
2126
0.020
Why?
Reagent Strips
1
2008
8
0.020
Why?
Primary Health Care
1
2019
1776
0.020
Why?
Urinalysis
1
2008
82
0.020
Why?
Albuminuria
1
2008
190
0.020
Why?
Diagnostic Tests, Routine
1
2008
109
0.020
Why?
Vision, Monocular
1
2005
4
0.010
Why?
Psychophysics
1
2005
15
0.010
Why?
Eye Enucleation
1
2005
16
0.010
Why?
Vision, Binocular
1
2005
47
0.010
Why?
Orientation
1
2005
50
0.010
Why?
Adolescent
2
2020
22557
0.010
Why?
Pattern Recognition, Visual
1
2005
105
0.010
Why?
Photic Stimulation
1
2005
265
0.010
Why?
Sensitivity and Specificity
1
2008
1998
0.010
Why?
Signal Transduction
1
2014
5246
0.010
Why?
Pregnancy
1
2008
7230
0.010
Why?
Child
1
2005
22693
0.000
Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)